Therapeutic Actions of Allylmercaptocaptopril and Captopril in a Rat Model of Metabolic Syndrome

American Journal of Hypertension

Volumn 20, Issue 8, 2007, Pages 866-874

  Ernsberger, Paul ^a   Johnson, Janean L ^a   Rosenthal, Talma ^b   Mirelman, David ^c   Koletsky, Richard J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

adipocytes; Angiotensin converting enzyme inhibitors; glomerulosclerosis; lipolysis; obesity

Indexed keywords

ALLYLMERCAPTOCAPTOPRIL; CAPTOPRIL; CATECHOLAMINE; CHOLESTEROL; CREATININE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIET RESTRICTION; DRUG ACTIVITY; FEMALE; FOOD INTAKE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; KOLETSKY RAT; LIPOLYSIS; MALE; METABOLIC SYNDROME X; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CAPTOPRIL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METABOLIC SYNDROME X; RATS; RATS, INBRED SHR; SULFINIC ACIDS; TREATMENT OUTCOME;

EID: 34547473573     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2007.02.015     Document Type: Article

References (30)

1. Ernsberger P., and Koletsky R.J. Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems. Naunyn Schmiedebergs Arch Pharmacol 373 (2006) 245-258
2. Ernsberger P., Koletsky R.J., and Friedman J.E. Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X. Ann NY Acad Sci 892 (1999) 272-288
3. Velliquette R.A., Kossover R., Previs S.F., and Ernsberger P. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn Schmiedebergs Arch Pharmacol 372 (2006) 300-312
4. Friedman J.E., Ishizuka T., Liu S., Farrell C.J., Bedol D., Koletsky R.J., Kaung H.L., and Ernsberger P. Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat. Am J Physiol 273 (1997) E1014-E1023
5. Koletsky R.J., Boccia J., and Ernsberger P. Acceleration of renal disease in obese SHR by exacerbation of hypertension. Clin Exp Pharmacol Physiol 22 Suppl (1995) S254-S256
6. Ernsberger P., Koletsky R.J., Collins L.A., and Bedol D.L. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central symaptholytic agent. Cardiovasc Drugs Ther 10 (1996) 275-282
7. Deedwania P.C. Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. Cardiol Clin 23 (2005) 139-152
8. Duarte J., Martinez A., Bermejo A., Vera B., Gamez M.J., Cabo P., and Zarzuelo A. Cardiovascular effects of captopril and enalapril in obese Zucker rats. Eur J Pharmacol 365 (1999) 225-232
9. Westenend P.J., Nooyen Y.A., van der Krogt J.A., Van Brummelen P., and Weening J.J. The effect of a converting enzyme inhibitor upon renal damage in spontaneously hypertensive Fawn Hooded rats. J Hypertens 10 (1992) 417-422
10. Tattelman E. Health effects of garlic. Am Fam Physician 72 (2005) 103-106
11. Elkayam A., Mirelman D., Peleg E., Wilchek M., Miron T., Rabinkov A., Oron-Herman M., and Rosenthal T. The effects of allicin on weight in fructose-induced hyperinsulinemic, hyperlipidemic, hypertensive rats. Am J Hypertens 16 (2003) 1053-1056
12. Elkayam A., Mirelman D., Peleg E., Wilchek M., Miron T., Rabinkov A., Sadetzki S., and Rosenthal T. The effects of allicin and enalapril in fructose-induced hyperinsulinemic hyperlipidemic hypertensive rats. Am J Hypertens 14 (2001) 377-381
13. Kannar D., Wattanapenpaiboon N., Savige G.S., and Wahlqvist M.L. Hypocholesterolemic effect of an enteric-coated garlic supplement. J Am Coll Nutr 20 (2001) 225-231
14. Oron-Herman M., Rosenthal T., Mirelman D., Miron T., Rabinkov A., Wilchek M., and Sela B.A. The effects of S-allylmercaptocaptopril, the synthetic product of allicin and captopril, on cardiovascular risk factors associated with the metabolic syndrome. Atherosclerosis 183 (2005) 238-243
15. Miron T., Rabinkov A., Peleg E., Rosenthal T., Mirelman D., and Wilchek M. Allylmercaptocaptopril: a new antihypertensive drug. Am J Hypertens 17 (2004) 71-73
16. Giudicelli J.F., Freslon J.L., Glasson S., and Richer C. Captopril and hypertension development in the SHR. Clin Exp Hypertens 2 (1980) 1083-1096
17. Swislocki A.L., LaPier T.L., Khuu D.T., Fann K.Y., Tait M., and Rodnick K.J. Metabolic, hemodynamic, and cardiac effects of captopril in young, spontaneously hypertensive rats. Am J Hypertens 12 (1999) 581-589
18. Vikari J. Precipitation of plasma lipoproteins by PEG-6000 and its evaluation with electrophoresis and ultracentrifugation. Scand J Clin Lab Invest 36 (1976) 265-268
19. Peterson G.L. A simplification of the protein assay method of Lowry et al which is more generally applicable. Anal Biochem 83 (1977) 346-356
20. Edwards L., and Ernsberger P. Assay of arachidonic acid release coupled to alpha 1- and alpha 2-adrenergic receptors. Methods Mol Biol 126 (2000) 375-390
21. Velliquette R.A., Koletsky R.J., and Ernsberger P. Plasma glucagon and free fatty acid responses to a glucose load in the obese spontaneous hypertensive rat (SHROB) model of metabolic syndrome X. Exp Biol Med 227 (2002) 164-170
22. Velliquette R.A., and Ernsberger P. The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther 306 (2003) 646-657
23. Cao Z., Bonnet F., Davis B., Allen T.J., and Cooper M.E. Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin Sci 100 (2001) 591-599
24. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D., and The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329 (1993) 1456-1462
25. Engeli S., Schling P., Gorzelniak K., Boschmann M., Janke J., Ailhaud G., Teboul M., Massiera F., and Sharma A.M. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. Int J Biochem Cell Biol 35 (2003) 807-825
26. Cabassi A., Coghi P., Govoni P., Barouhiel E., Speroni E., Cavazzini S., Cantoni A.M., Scandroglio R., and Fiaccadori E. Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat. J Clin Endocrinol Metab 90 (2005) 2888-2897
27. Houstis N., Rosen E.D., and Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440 (2006) 944-948
28. Thirunavukkarasu V., Anitha Nandhini A.T., and Anuradha C.V. Lipoic acid attenuates hypertension and improves insulin sensitivity, kallikrein activity and nitrite levels in high fructose-fed rats. J Comp Physiol [B] 174 (2004) 587-592
29. Vasdev S., Gill V., Parai S., and Gadag V. Dietary lipoic acid supplementation attenuates hypertension in Dahl salt sensitive rats. Mol Cell Biochem 275 (2005) 135-141
30. Endo K., Miyashita Y., Sasaki H., Ohira M., Saiki A., Koide N., Otsuka M., Oyama T., Takeyoshi M., Ito Y., and Shirai K. Probucol delays progression of diabetic nephropathy. Diabetes Res Clin Pract 71 (2006) 156-163